Business Context and Reporting Period
This Form 6-K filing by Quoin Pharmaceuticals, Ltd. covers the month of November 2022. The report details the outcomes of the Company's Annual General Meeting held on November 3, 2022, and discloses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. However, it references a prior audit report dated April 13, 2022, which included an emphasis of matter regarding the Company's ability to continue as a going concern. The financial statements for the years ended December 31, 2021, and 2020 were prepared assuming the Company will continue as a going concern.
Material Changes
- Share Capital Increase: Shareholders approved an increase in registered share capital from 50,000,000,000 ordinary shares to 500,000,000,000 ordinary shares (of no par value).
- Accounting Firm Change: The Company transitioned from Friedman LLP to Marcum LLP as its independent registered public accounting firm, effective September 1, 2022, following a combination of the two firms. This change was approved by shareholders at the Annual General Meeting.
- Board Elections: Shareholders approved the reelection of Michael Myers, Denise Carter, Joseph Cooper, James Culverwell, Dennis H. Langer, Natalie Leong, and Michael Sember to the Board of Directors.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary on future operations. The primary risk disclosed is the historical "going concern" uncertainty noted in the prior audit report, though management's plan to address this was described in Note 2 of the previous financial statements. The Company explicitly states that the change in auditors was not the result of any disagreement on accounting principles, practices, or auditing scope.
Investor Verification Checklist
- Verify the details of the share capital increase and its potential impact on dilution in the Company's Articles of Association.
- Review the "going concern" emphasis of matter in the audited financial statements for the years ended December 31, 2021, and 2020, and assess current liquidity status.
- Confirm the transition timeline and scope of work between the former auditor (Friedman LLP) and the new auditor (Marcum LLP).
- Check for any subsequent filings regarding the Company's ability to meet its financial obligations given the historical going concern warning.